AstraZeneca PLC (AZN)
| Market Cap | 208.77B |
| Revenue (ttm) | 45.00B |
| Net Income (ttm) | 5.90B |
| Shares Out | 3.10B |
| EPS (ttm) | 1.89 |
| PE Ratio | 35.63 |
| Forward PE | 16.16 |
| Dividend | $1.45 (2.15%) |
| Ex-Dividend Date | Aug 10, 2023 |
| Volume | 3,354,720 |
| Open | 67.38 |
| Previous Close | 67.30 |
| Day's Range | 67.04 - 67.52 |
| 52-Week Range | 61.73 - 76.56 |
| Beta | 0.17 |
| Analysts | Strong Buy |
| Price Target | 81.00 (+20.27%) |
| Earnings Date | Feb 8, 2024 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, ... [Read more]
Financial Performance
In 2022, AstraZeneca's revenue was $44.35 billion, an increase of 18.53% compared to the previous year's $37.42 billion. Earnings were $3.29 billion, an increase of 2835.71%.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for AZN stock is "Strong Buy." The 12-month stock price forecast is $81.0, which is an increase of 20.27% from the latest price.
News
AstraZeneca buys Chinese cancer therapy firm Gracell for $1.2bn
Gracell Biotechnologies acquisition marks China's growing importance to the Anglo-Swedish drugmaker
AstraZeneca to buy China's Gracell Biotechnologies in $1.2 billion deal
Dec 26 (Reuters) - AstraZeneca (AZN.L) said on Tuesday it will buy Gracell Biotechnologies (GRCL.O) for up to $1.2 billion as the Anglo-Swedish pharma company furthers its cell therapy ambitions and b...
AstraZeneca to Acquire China's Gracell in $1.2 Billion Deal to Further Cell Therapy Goals
AstraZeneca's acquisition of Gracell is expected to close in the first quarter of 2024.
Ionis Pharmaceuticals, AstraZeneca get FDA approval for rare genetic disease treatment
Ionis Pharmaceuticals IONS, +1.61% and AstraZeneca's AZN, +0.79% Wainua has been approved by the U.S. Food and Drug Administration for treating a symptom of a rare genetic disease.
US FDA approves Ionis-AstraZeneca's nerve disease drug
The U.S. Food and Drug Administration (FDA) on Thursday approved Ionis Pharmaceuticals and partner AstraZeneca's drug to treat nerve damage caused by a life-shortening rare disease.
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Dosing of first patient in Phase 3 trial of rilvegostomig, a PD-1/TIGIT bispecific antibody, will trigger $10 million milestone payment from AstraZeneca HOLON, Israel , Dec. 19, 2023 /PRNewswire/ -- C...
Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patient has been dosed in two global, randomized phase 3 trials evaluating the efficacy and safety of Daiichi Sankyo (TSE: 4568) and AstraZeneca...
AstraZeneca, Sanofi to supply 230,000 more RSV infant shots to US market
The makers of a respiratory syncytial virus (RSV) immunization for infants that has been in tight supply will deliver an additional 230,000 doses in January, the White House said on Thursday, after U....
Why AstraZeneca Is Buying Icosavax For $1.1 Billion
Shares of Icosavax (ICVX) skyrocketed over 48% in early trading Tuesday after AstraZeneca (AZN) agreed to purchase the biopharma company for $1.1 billion to expand its reach into cutting-edge vaccine ...
AstraZeneca will pay up to $1.1B to acquire Icosavax, a Univ. of Washington biotech spinout
Seattle-based Icosavax, a spin-out from the University of Washington's Institute for Protein Design, will be acquired by biotech giant AstraZeneca for up to $1.
AstraZeneca buys US vaccine company in $1.1bn deal
Britain's biggest drugmaker buying Seattle-based firm Icosavax, expanding vaccine and immune therapy business
This Vaccine Stock Soars 46% After $1.1 Billion AstraZeneca Deal
AstraZeneca agreed to acquire respiratory vaccine developer Icosavax in a cash deal expected to close in the first quarter of next year.
AstraZeneca Will Acquire RSV Vaccine Developer Icosavax For $1.1 Billion
AstraZeneca has agreed to acquire U.S.-based vaccine developer Icosavax for $1.1 billion, the companies announced Tuesday, to gain access to experimental vaccines targeting common respiratory disease-...
AstraZeneca to buy RSV vaccine maker Icosavax for $1.1 bln
Drugmaker AstraZeneca on Tuesday agreed to buy vaccine developer Icosavax in a deal valued at up to $1.1 billion to bolster its respiratory syncytial virus (RSV) vaccine portfolio.
AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT
Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, the Financial Times re...
AstraZeneca to scrap two trials on drug that curbs potassium
AstraZeneca on Friday said it would discontinue two late-stage trials looking at the potential benefits of its drug Lokelma in the management of hyperkalaemia across the cardiorenal spectrum.
Presage Biosciences Announces New Pharma Partnership to Evaluate Novel Immuno-Oncology Drug Combinations with CIVO® Technology
SEATTLE , Nov. 30, 2023 /PRNewswire/ -- Presage Biosciences, a pioneering translational oncology company whose mission is to use CIVO and spatial molecular profiling to understand the complexity of dr...
AstraZeneca advances scientific leadership in hematology at ASH 2023
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will present new clinical and real-world data in multiple hematological conditions at the 65th American Society of Hematology (ASH) Annual Meeting andExp...
U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for AstraZeneca's Truqap™ (capivasertib) in combination with Faslodex® (fulvestrant) to Identify Patients with HR-Positive, HER2-Negative Advanced Breast Cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx to be used as a compani...
AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today launches Evinova, set to be a leading provider of digital health solutions to better meet the needs of healthcare professionals, regulators and pat...
3 stocks that crushed earnings estimates and still tanked
Stocks that crush their earnings estimates are supposed to go up. However, that's not always the case.
Third Success from Astex Drug Discovery Pharma Collaboration and Licence Agreements as AstraZeneca Receives US Marketing Approval for Cancer Drug Truqap (capivasertib)
AstraZeneca's Truqap™ (capivasertib) in combination with Faslodex® (fulvestrant) receives US FDA marketing approval for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negati...
CDC expedites release of more doses of infant RSV drug from Sanofi, AstraZeneca amid shortage
The CDC's move to increase availability of Beyfortus, a monoclonal antibody from Sanofi and AstraZeneca, comes as RSV cases rise in some parts of the country.
US FDA approves AstraZeneca's breast cancer drug combination
The U.S. Food and Drug Administration on Thursday approved AstraZeneca's drug capivasertib in combination with an older drug, providing another treatment option for patients with the most common type ...